The authors summarised pathophysiology and
therapy possibility of the chronic
alcoholic pancreatitis. They introduce a new product of
pancreatin use for treatment of chronic
alcoholic pancreatitis. The aim of this prospective study was to asses the efficacy of this new
drug in the treatment of chronic
alcoholic pancreatitis. The treatment was carried out by new
pancreatin product containing 10,000 FIP U
lipase, 9000 FIP U
amylase, and 500 FIP E
protease. During the study 30 patients--suffering from
alcoholic pancreatitis--were treated. They received, two
tablets three times daily in a period of two weeks. The following parameters were observed and compared before and after the period of treatment: complaints of the patients, the characteristics of the stool (daily weight, frequency, fat contents, consistency) the change of the
body weight and degree of
abdominal pain. These parameters were compared using a score-system, before and after the period of treatment. The authors could analyse the data of 21 patients. It was proved that there was a significant decrease in frequency, daily weight and fat contents of the stool and in
abdominal pain. There was not significant change in the
body weight. The authors concluded that this new product is a good
pancreatin preparation which is useful and suitable for effective treatment of chronic
alcoholic pancreatitis, if the patient keeps abstinence.